Recent events
Recent events tied to this brand in public sources.
Back to profile61 entries · Page 1 of 4
2026
Seawolf launches with $100 million in funding
Seawolf Therapeutics launched publicly with $100 million in funding. The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics and others.
2026
LifeMD finalizes branded GLP-1 fulfillment arrangements with Eli Lilly and Novo Nordisk
LifeMD finalized arrangements with Eli Lilly and Novo Nordisk to fulfill and ship their branded GLP-1 medications through LifeMD's pharmacy. Management said this could add revenue and gross profit dollars from prescriptions previously fulfilled through third parties.
2026
Former Eli Lilly representative sues over alleged Mounjaro marketing
Former Eli Lilly sales representative Jennifer Mansion sued the company, alleging retaliation after she objected to Lilly's alleged promotion of Mounjaro for weight loss, a use described in the complaint as not approved at the time. The retaliation charge remains an allegation, not an established court finding.
2026
PHI Health sues employers over arbitration awards
PHI Health has sued hundreds of employers to collect unpaid arbitration awards under the federal No Surprises Act. The article says the employer cases are still pending.
2026
Eli Lilly raises its 2026 revenue outlook
Eli Lilly raised its expected 2026 revenue range to $91 billion–$92 billion, from its previous guidance of $85 billion–$87 billion.
2026
METiS TechBio and Eli Lilly announce drug-delivery partnership
METiS TechBio and Eli Lilly announced a partnership to develop lipid nanoparticle-based delivery solutions, combining METiS's AI-driven lipid design with Lilly's drug discovery, development, and commercialization expertise. The deal is worth up to approximately $1.1 billion in potential milestone payments, in addition to an upfront payment and potential royalties.
2026
Eli Lilly weight-loss pill receives EU regulator backing
Reuters reports that Eli Lilly's weight-loss pill received backing from an EU drug regulator; the headline does not specify the date or details of the backing.
2026
Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicity
A patient has filed a lawsuit against Eli Lilly, alleging stomach problems that the patient ties to the medications Mounjaro and Trulicity, as reported by The Indiana Lawyer.
2026
Eli Lilly reports Phase 2 results showing eloralintide plus tirzepatide produced substantially more weight loss
Eli Lilly reported Phase 2 trial data showing that its experimental amylin-targeting drug eloralintide, when combined with tirzepatide (the active ingredient in its Zepbound and Mounjaro shots), produced substantially more weight loss in patients with obesity and Type 2 diabetes. At 48 weeks, the highest-dose combination group lost an average of 23.3% of body weight versus 14.8% on a high dose of tirzepatide alone. More patients on the combination discontinued treatment due to side effects (10.8% to 27% depending on dose) than on tirzepatide alone (2.9%), and Lilly needs to confirm the results in Phase 3 trials that will begin later this year.
2026
Eli Lilly breaks ground on $6.5 billion Houston manufacturing facility to ramp up Foundayo production
Eli Lilly broke ground on its planned $6.5 billion manufacturing facility at Generation Park in Houston, Texas, which the company expects to be operational by 2030 and which will produce ingredients for the Foundayo obesity pill and other small-molecule medicines.
2026
Eli Lilly launches oral weight-loss drug Foundayo in the UK
Eli Lilly launched its oral weight-management and type 2 diabetes drug Foundayo (orforglipron) in the UK via private prescription, making Britain the first country in Europe where the oral treatment is available. The drug was authorised by Britain's medicines regulator on August 10, and Lilly said it is working with NICE during the agency's assessment for weight management access.
2026
Eli Lilly files lawsuits against six companies over alleged illegal retatrutide sales
Eli Lilly filed six lawsuits against Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide, alleging they sell counterfeit, unapproved versions of its investigational diabetes and obesity drug retatrutide, which is not yet FDA approved.
2026
Illumina introduces Billion Cell Atlas
Illumina introduced the Illumina Billion Cell Atlas, a genome-wide genetic perturbation dataset intended to support AI drug discovery. The program aims to build a five-billion-cell atlas over three years, with AstraZeneca, Merck and Eli Lilly participating under an alliance framework.
2024
Baltimore sues insulin manufacturers and pharmacy benefit managers over pricing
The City of Baltimore filed a federal racketeering lawsuit against Eli Lilly, Sanofi, Novo Nordisk, CVS, Express Scripts and OptumRx, alleging that the companies conspired to artificially raise insulin prices. The lawsuit also raises civil conspiracy, antitrust and unjust enrichment claims; the allegations are not determinations of wrongdoing. Eli Lilly called the complaint “baseless”; CVS and Novo Nordisk said they would defend against the claims, Sanofi said its pricing practices complied with the law, and Optum said the lawsuit was without merit.
2024
Baltimore files insulin-pricing lawsuit against drugmakers and pharmacy benefit managers
Baltimore filed a lawsuit against Eli Lilly, Novo Nordisk, CVS and other companies, alleging they conspired to raise the prices of insulin and other diabetes medications and violated state antitrust and consumer protection laws and the RICO Act. The allegations have not been adjudicated in the supplied report.
2024
Firefly Bio emerges from stealth with $94 million
Firefly Bio emerged from stealth with $94 million in financing. Its Series A round was co-led by Versant and MPM BioImpact, with Decheng Capital and Eli Lilly also participating.
2024
Lilly legal actions over products claiming to contain tirzepatide
Eli Lilly said it had commenced legal action against certain medical spas, wellness centers, compounding pharmacies, importers, distributors, and counterfeit sources over products claiming to contain tirzepatide or falsely claiming to sell Mounjaro or Zepbound.
2023
FDA approves Eli Lilly obesity treatment
The U.S. Food and Drug Administration approved Eli Lilly's weight-loss drug and obesity treatment; the drug is to be marketed as Zepbound.
2023
Eli Lilly sues 11 online pharmacies over products claiming to contain tirzepatide
Eli Lilly said it sued 11 online pharmacies to stop them from importing, selling and distributing products claiming to contain the active ingredient in its diabetes drug Mounjaro. Lilly accused the pharmacies of trademark infringement, falsely associating themselves with Lilly and approved tirzepatide, and making false or misleading advertising statements.
2023
Eli Lilly sues sellers of products marketed as Mounjaro
Eli Lilly said it had filed four lawsuits against medical spas, wellness centers and compounding pharmacies over sales or advertising of compounded tirzepatide as Mounjaro. Lilly accused the defendants of violating consumer protection and competition laws and infringing its trademark; it sought orders barring sales and unspecified damages.